Thromb Haemost
DOI: 10.1055/s-0040-1718531
Coagulation and Fibrinolysis

Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case–Cohort Study on Italian Women: Results from the Moli-sani Study

Simona Costanzo
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Roberta Parisi
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Amalia De Curtis
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Sara Gamba
2  Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Laura Russo
2  Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Mariarosaria Persichillo
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Teresa Panzera
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Marina Marchetti
2  Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
,
Chiara Cerletti
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Giovanni de Gaetano
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Anna Falanga
2  Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
3  School of Medicine, University of Milan Bicocca, Monza, Italy
,
Maria Benedetta Donati
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
,
Licia Iacoviello
1  Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Isernia, Italy
4  Department of Medicine and Surgery, Research Center in Epidemiology and Preventive Medicine (EPIMED), University of Insubria, Varese, Italy
,
on behalf of the Moli-sani Investigators› Author Affiliations
Funding The analyses conducted in this study were partially supported by the HYPERCAN Study (AIRC “5xMILLE” no. 12237) and by POR FESR 2014-2020: DD no. 459 del 27/11/2018 (SATIN: Sviluppo di Approcci Terapeutici INnovativi per patologie neoplastiche resistenti ai trattamenti). The enrolment phase of the Moli-sani Study was supported by unrestricted research grants from the Pfizer Foundation (Rome, Italy), the Italian Ministry of University and Research (MIUR, Rome, Italy)—Programma Triennale di Ricerca, Decreto no.1588, and Instrumentation Laboratory, Milan, Italy.
The follow-up phase of the Moli-sani Study (assessment of incident cases) was partially supported by AIRC “5xMILLE” (HYPERCAN Study, n. 12237) and the Italian Ministry of Health (PI GdG, CoPI SC; grant no. RF-2018-12367074).
No funder had a role in study design, collection, analysis, interpretation of data, writing of the manuscript, and decision to submit this article for publication.

Abstract

Background Elevated levels of key enzymes of the fibrinolytic system, such as tissue plasminogen activator (tPA), are reported as predictors of poor outcome in cancer patients. Limited information is available about their potential predictive value for breast cancer (BC) risk in the general population.

Aim We examined the association of tPA levels with BC risk in a case–cohort study including women from the prospective Moli-sani cohort.

Methods A sample of 710 women (mean age: 54.6 ± 12.1 years) was selected as a subcohort and compared with 84 BC cases, in a median follow-up of 4.2 years. Incident cases of BC were validated through medical records. tPA plasma levels were measured using an enzyme-linked immunosorbent assay kit. Hazard ratio (HR) and 95% confidence interval (CI), adjusted for relevant covariates, were estimated by a Cox regression model using the Prentice method.

Results Compared with the lowest quartile (<4.9 ng/mL), women in the highest quartile of tPA (>11.2 ng/mL) had increased risk of BC (HRIVvsI: 2.20, 95% CI: 1.13–4.28) after adjusted for age, smoking, education, menopause, and residence. Further adjustment for biochemical markers did not modify this association. The risk of BC increased by 34% for each increase in 1 standard deviation of log-transformed tPA levels (p = 0.046). Elevated levels of tPA were associated mainly with estrogen-receptor-positive BC (2.08, 95% CI: 1.18–3.66).

Conclusion Higher levels of tPA, reported to predict cardiovascular risk, are a potential biomarker for BC risk, supporting the hypothesis of a “common soil” linking the pathogenic mechanisms of hormone-dependent tumors and cardiovascular disease.

Authors' Contributions

A.F, L.I., M.B.D, and M.M. contributed to the concept and design of the work and interpretation of data; S.G. and L.R. performed the tPA measurements; S.C., A.D.C. S.G., L.R., M.M., T.P., and M.P. managed data collection; S.C. analyzed the data and reviewed the manuscript; R.P. wrote the manuscript; C.C., M.B.D., A.F., G.d.G., and L.I. originally inspired the research and critically reviewed the manuscript.


* [Supplementary Appendix A] lists all the Moli-sani Investigators.


Supplementary Material



Publication History

Received: 08 May 2020

Accepted: 02 September 2020

Publication Date:
18 October 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York